The efficacy of EGFR inhibition is likely to at least in part be driven by the reshaping of the tumour immune microenvironment, with higher infiltration and proliferation of anti-tumour T cells observed in mouse models following EGFR inhibition (131). This evidence concerns the gene EGFR and neoplasm.